Abstract: An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metal-lofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.

Abstract: An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metallofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.

Abstract: Provided is an application of a fullerene/metal-fullerene micro/nanomaterial for preparing a pharmaceutical product. The pharmaceutical product has at least one of the following properties: 1) treats a bone marrow suppression; 2) treats at least one of the following conditions caused by the bone marrow suppression: white blood cell count reduction, platelet count reduction, hemo-globin count reduction, and monocyte count reduction; 3) protects a bone marrow cell and/or a hematopoietic cell; 4) able to build up in a bone marrow; 5)protects the liver, spleen, and kidneys; 6) removes a free radical; and 7) improves the performance of an antioxidant system in an organism.

Abstract: An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metal-lofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.